{"id":"https://openalex.org/W2334543757","doi":null,"title":"ACP-103, a 5-HT2A receptor inverse agonist.","display_name":"ACP-103, a 5-HT2A receptor inverse agonist.","publication_year":2006,"publication_date":"2006-07-01","ids":{"openalex":"https://openalex.org/W2334543757","mag":"2334543757","pmid":"https://pubmed.ncbi.nlm.nih.gov/16869120"},"language":"en","primary_location":{"id":"pmid:16869120","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16869120","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111662683","display_name":"Claire Roberts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Claire Roberts","raw_affiliation_strings":["Psychiatry Centre of Excellence for Drug Discovery, New Frontiers Science Park, GlaxoSmithKline plc, Harlow, UK. Claire.Roberts@gsk.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry Centre of Excellence for Drug Discovery, New Frontiers Science Park, GlaxoSmithKline plc, Harlow, UK. Claire.Roberts@gsk.com","institution_ids":["https://openalex.org/I188950975"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5111662683"],"corresponding_institution_ids":["https://openalex.org/I188950975"],"apc_list":null,"apc_paid":null,"fwci":1.7716,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.8466476,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"7","issue":"7","first_page":"653","last_page":"60"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.4004000127315521,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.4004000127315521,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.26460000872612,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.2222999930381775,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/5-ht2a-receptor","display_name":"5-HT2A receptor","score":0.9729999899864197},{"id":"https://openalex.org/keywords/inverse-agonists","display_name":"inverse agonists","score":0.9729999899864197},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8399999737739563},{"id":"https://openalex.org/keywords/insomnia-treatment","display_name":"insomnia treatment","score":0.8309999704360962},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9850000143051147},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.8880000114440918},{"id":"https://openalex.org/keywords/dyskinesia","display_name":"dyskinesia","score":0.8610000014305115}],"concepts":[{"id":"https://openalex.org/C89951826","wikidata":"https://www.wikidata.org/wiki/Q1671731","display_name":"Inverse agonist","level":4,"score":0.7750840187072754},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.612472653388977},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6107189655303955},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.5721133351325989},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5490440130233765},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5386663675308228},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5250941514968872},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5194682478904724},{"id":"https://openalex.org/C3019878999","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic drug","level":4,"score":0.430569589138031},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4280587434768677},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.41960567235946655},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3789157271385193},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3629710078239441},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2906266450881958}],"mesh":[{"descriptor_ui":"D000075202","descriptor_name":"Contraindications","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D044402","descriptor_name":"Receptor, Serotonin, 5-HT2A","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:16869120","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16869120","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:2334543757","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16869120","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2035787500","https://openalex.org/W4235103004","https://openalex.org/W2112739763","https://openalex.org/W2044540277","https://openalex.org/W4210476495","https://openalex.org/W2161441546","https://openalex.org/W7095998939","https://openalex.org/W2074146160","https://openalex.org/W7052005567","https://openalex.org/W45020151"],"abstract_inverted_index":{"ACADIA":[0],"Pharmaceuticals":[1],"is":[2],"developing":[3],"ACP-103,":[4],"lead":[5],"compound":[6],"in":[7,30,33,39],"a":[8,15],"series":[9],"of":[10,24,52],"5-HT2A":[11],"inverse":[12],"agonists,":[13],"as":[14,44],"potential":[16,22],"antipsychotic":[17],"agent":[18],"and":[19,38,58],"for":[20],"the":[21,50,53],"treatment":[23],"insomnia.":[25],"Phase":[26],"II":[27,47],"clinical":[28],"trials":[29,48],"treatment-induced":[31],"psychosis":[32],"Parkinson's":[34],"disease":[35],"(PD)":[36],"patients":[37,41],"schizophrenic":[40],"are":[42,45],"ongoing,":[43],"phase":[46],"evaluating":[49],"effects":[51],"drug":[54],"on":[55],"PD":[56],"symptoms":[57],"dyskinesias.":[59]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}